The cGAS‐STING pathway plays a significant role in enhancing the immune response by activating innate immunity, and therefore has been recognized as the next‐generation cancer immunotherapy.[1] In this pathway, cGAS binds to double‐stranded DNA (dsDNA), triggering a catalytic activity that results in the production of cGAMP, which then stimulates type I interferon (IFN‐I) responses.[2] In addition, the binding of STING and cyclic dinucleotides (CDNs),[3] as well as the endoplasmic reticulum  stress‐mediated STING shift[4] are also ways to activate the cGAS‐STING pathway. The gene discussed is CGAS; the disease is cancer.